$VERA

Vera Therapeutics (VERA) reported positive final trial results for TRUTAKNA, meeting all endpoints in the ORIGIN 3 trial for IgA nephropathy. The data showed strong kidney function preservation and safety comparable to placebo. The company plans to use the data for a supplemental BLA filing in late 2026, which could expand TRUTAKNA's label. Vera Therapeutics currently has no meaningful revenue and a net loss of $401.9M, with a share price down 33% year-to-date.

Vera Therapeutics (VERA) shares rose after the company reported final Phase 3 data showing its kidney drug TRUTAKNA reduced disease progression risk by 76% and stabilized kidney function. The results support a planned FDA filing for late 2026, with strong early launch metrics and heavy options trading. However, the company has no product revenue, rising losses, and cash burn, requiring successful sales and potential capital raising to sustain operations.

Vera Therapeutics reported that TRUTAKNA met all endpoints in the Phase III ORIGIN 3 trial for IgA nephropathy, with strong kidney function data and a safety profile comparable to placebo. The company plans to seek full FDA approval in late 2026. According to the company, TRUTAKNA's self-administered format and early commercial momentum indicate a focus on real-world adoption. The therapy's potential as a disease-modifying treatment could reshape Vera's investment narrative, though the company r

Fordyce Marshall (PRESIDENT AND CEO) sold 18,500 shares of Vera Therapeutics, Inc. (VERA) at $37.00 ($0.68M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Vicor Corp (VICR) shares rose 13.5% to $208.73 after granting a license for its patents. Other stocks gaining include Securitize (SECZ) +21%, Generac (GNRC) +19.6%, and Arm (ARM) +6.7%. Generac's rise follows a supply deal with Amazon and a price target increase. Micron (MU) gained 5.6% amid a memory stock rally.

Vera Therapeutics reported positive two-year Phase 3 trial results for Trutakna, showing a 76% reduction in kidney-disease progression risk vs. placebo. The drug met all efficacy endpoints and demonstrated improved kidney function. Vera plans to submit for full FDA approval in Q4 2026, aiming for a 2027 decision. The company has seen early commercial adoption with 350+ patient starts in 10 weeks.

Vera Therapeutics (VERA) reported that TRUTAKNA stabilized kidney function in IgA nephropathy patients over two years in the ORIGIN 3 trial. The company plans to submit a supplemental Biologics License Application in Q4 2026. Shares rose 12% following the update. The trial met all endpoints, showing a 5.0mL/min/1.73m2 benefit in kidney filtration rates compared to placebo.

Vera Therapeutics' stock rose 14% in pre-market trading after its drug TRUTAKNA met all endpoints in a Phase 3 trial, showing significant kidney function preservation. The company plans to submit a supplemental FDA application in Q4 2026. This news is notable amid a broader market downturn due to Fed meeting expectations and AI safety concerns.

Vera Therapeutics (VERA) reported that TRUTAKNA met all endpoints in the ORIGIN 3 trial for IgA nephropathy, showing eGFR stabilization and reduced disease progression. The company plans to submit for full FDA approval in Q4 2026 and has seen strong commercial launch momentum with over 350 patient start forms in 10 weeks.

Fordyce Marshall (PRESIDENT AND CEO) sold 18,500 shares of Vera Therapeutics, Inc. (VERA) at $35.12 ($0.65M total) on 2026-09-02 under a Rule 10b5-1 trading plan.